mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern-Reference-Cited by-同舟云学术

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Published:2021-12-03 Issue:6572 Volume:374 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Goel Rishi R.¹²^ORCID,Painter Mark M.¹²^ORCID,Apostolidis Sokratis A.¹²³^ORCID,Mathew Divij¹²^ORCID,Meng Wenzhao¹⁴^ORCID,Rosenfeld Aaron M.¹⁴^ORCID,Lundgreen Kendall A.⁵^ORCID,Reynaldi Arnold⁶^ORCID,Khoury David S.⁶,Pattekar Ajinkya²^ORCID,Gouma Sigrid⁵^ORCID,Kuri-Cervantes Leticia¹⁵^ORCID,Hicks Philip⁵^ORCID,Dysinger Sarah⁵^ORCID,Hicks Amanda²^ORCID,Sharma Harsh²^ORCID,Herring Sarah²^ORCID,Korte Scott²^ORCID,Baxter Amy E.¹^ORCID,Oldridge Derek A.¹⁴^ORCID,Giles Josephine R.¹⁷⁸^ORCID,Weirick Madison E.⁵^ORCID,McAllister Christopher M.⁵^ORCID,Awofolaju Moses⁵^ORCID,Tanenbaum Nicole⁵^ORCID,Drapeau Elizabeth M.⁵^ORCID,Dougherty Jeanette¹^ORCID,Long Sherea¹^ORCID,D’Andrea Kurt¹^ORCID,Hamilton Jacob T.²⁵^ORCID,McLaughlin Maura¹,Williams Justine C.²^ORCID,Adamski Sharon²^ORCID,Kuthuru Oliva¹^ORCID,Frank Ian⁹^ORCID,Betts Michael R.¹⁵^ORCID,Vella Laura A.¹⁰^ORCID,Grifoni Alba¹¹^ORCID,Weiskopf Daniela¹¹^ORCID,Sette Alessandro¹¹¹²^ORCID,Hensley Scott E.⁵^ORCID,Davenport Miles P.⁶^ORCID,Bates Paul⁵^ORCID,Luning Prak Eline T.¹⁴^ORCID,Greenplate Allison R.¹²^ORCID,Wherry E. John¹²⁷⁸^ORCID,

Affiliation:

1. Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

2. Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

3. Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

4. Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

5. Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

6. Kirby Institute, University of New South Wales, Sydney, NSW, Australia.

7. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

8. Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

9. Division of Infectious Disease, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

10. Division of Infectious Disease, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA.

11. Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.

12. Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego (UCSD), La Jolla, CA, USA.

Abstract

Immune memory after vaccination Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven highly effective at preventing severe COVID-19. However, the evolution of viral variants, and waning antibody levels over time, raise questions regarding the longevity of vaccine-induced immune protection. Goel et al . examined B and T lymphocyte responses in individuals who received SARS-CoV-2 messenger RNA vaccines. They performed a 6-month longitudinal study of individuals who never had SARS-CoV-2 infection compared with people who had recovered from SARS-CoV-2. Humoral and cellular immune memory was observed in vaccinated individuals, as were functional immune responses against the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) viral variants. Analysis of T cell activity suggested that robust cellular immune memory may prevent hospitalization by limiting the development of severe disease. —PNK

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference65 articles.

1. The first 12 months of COVID-19: a timeline of immunological insights

2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

3. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

4. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

5. D. Cromer M. Steain A. Reynaldi T. E. Schlub A. K. Wheatley J. A. Juno S. J. Kent J. A. Triccas D. S. Khoury M. P. Davenport SARS-CoV-2 variants: levels of neutralisation required for protective immunity. medRxiv 2021.08.11.21261876 [Preprint] (2021). .10.1101/2021.08.11.21261876 2021.08.11.21261876

Cited by 558 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Advances on Swine Acute Diarrhea Syndrome Coronavirus;Animals;2024-01-30

2. Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice;Applied Microbiology and Biotechnology;2024-01-27

3. Non-classical CD45RBlo memory B-cells are the majority of circulating antigen-specific B-cells following mRNA vaccination and COVID-19 infection.;2024-01-25

4. Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning;Annual Review of Pathology: Mechanisms of Disease;2024-01-24

5. Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine;Frontiers in Immunology;2024-01-04